Please assess the completion status of the following clinical trial:

Trial Title: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in acute treatment for binge-eating disorder and obesity;~* Did not have a positive response to acute treatment;~* Available for the duration of the treatment and follow-up (20 months);~* Read, comprehend, and write English at a sufficient level to complete study-related materials; and~* Able to travel to study location (New Haven, CT) for weekly visits.~Exclusion Criteria:~* Currently taking anti-depressant medications;~* Currently taking opioid pain medications or drugs;~* Currently taking medications that influence eating/weight;~* History of seizures;~* Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality);~* Past or current anorexia nervosa, bulimia nervosa;~* Pregnant or breastfeeding;~* Medical status judged by study physician as contraindication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive-Behavioral Therapy (CBT) (Type: EXPERIMENTAL): CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse.
- Naltrexone/bupropion (NB) (on-going from acute stage) (Type: ACTIVE_COMPARATOR): Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).